LCM
KLDO

Laurion Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Laurion Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-51,360
Closed -$382K – 1246
2020
Q2 		$382K Buy
+51,360
New +$344K ﹤0.01% 675

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laurion Capital Management's KLDO Position: Q3 2020 in Review

Laurion Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2020, closing a stake of 51,360 shares — an estimated $382K sold.

Laurion Capital Management first reported a position in KLDO in Q2 2020 and held it in 1 quarter. The position peaked at $382K in Q2 2020. 56 funds tracked by Wall St. Rank hold KLDO as of Q3 2020.

  • Laurion Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Laurion Capital Management sold 51,360 Kaleido Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $382K.
  • Laurion Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Laurion Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $382K in Q2 2020.
  • 56 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2020.

Based on Laurion Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.